Thomas Beetham
Direttore operativo presso VIRIDIAN THERAPEUTICS, INC.
Patrimonio netto: - $ in data 30/04/2024
Profilo
Thomas W.
Beetham was the founder of Kiniksa Pharmaceuticals Ltd.
(founded in 2015) where he held the title of Secretary, Chief Legal Officer & EVP-Operations from 2019 to 2021.
He is currently the Chief Operating Officer at Viridian Therapeutics, Inc. since 2023.
Mr. Beetham's former positions include being an Attorney at Genzyme Corp.
from 2004 to 2011, an Attorney at Palmer & Dodge LLP from 1999 to 2004, General Legal Counsel at New England Biolabs, Inc. from 2011 to 2013, Chief Legal Officer, Senior VP & General Counsel at Synageva BioPharma Corp.
from 2013 to 2015, Secretary & Chief Legal Officer at Dianthus Therapeutics, Inc. from 2021 to 2023, and Chief Legal Officer at Magenta Therapeutics, Inc. from 2021 to 2023.
Mr. Beetham's education history includes an undergraduate degree from Rochester Christian University, graduate and MBA degrees from Boston College, and a graduate degree from Boston College Law School.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
01/04/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Posizioni attive di Thomas Beetham
Società | Posizione | Inizio |
---|---|---|
VIRIDIAN THERAPEUTICS, INC. | Direttore operativo | 30/10/2023 |
Precedenti posizioni note di Thomas Beetham
Società | Posizione | Fine |
---|---|---|
DIANTHUS THERAPEUTICS, INC. | Consigliere Generale | 01/09/2023 |
MAGENTA THERAPEUTICS | Consigliere Generale | 01/09/2023 |
KINIKSA PHARMACEUTICALS, LTD. | Fondatore | 01/06/2021 |
SYNAGEVA BIOPHARMA CORP | Consigliere Generale | 01/06/2015 |
New England Biolabs, Inc.
New England Biolabs, Inc. Chemicals: SpecialtyProcess Industries New England Biolabs, Inc. produces and supplies reagents for the life science industry. The firm?s products include restriction endonucleases, PCR, qPCR and amplification technologies, DNA modifying enzymes, sample preparation for next generation sequencing, nucleic acid purification, DNA assembly, cloning and mutagenesis kits, genome editing, competent cells, markers and ladders, RNA reagents, gene expression, cellular analysis, epigenetics, protein tools, DNA plasmids, glycobiology, protein expression and purification technologies. The company was founded by Donald Comb in 1974 and is headquartered in Ipswich, MA. | Consigliere Generale | 01/10/2013 |
Formazione di Thomas Beetham
Rochester Christian University | Undergraduate Degree |
Wallace E Carroll School of Management | Masters Business Admin |
Boston College Law School | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
VIRIDIAN THERAPEUTICS, INC. | Health Technology |
DIANTHUS THERAPEUTICS, INC. | Health Technology |
Aziende private | 5 |
---|---|
Synageva BioPharma Corp.
Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
New England Biolabs, Inc.
New England Biolabs, Inc. Chemicals: SpecialtyProcess Industries New England Biolabs, Inc. produces and supplies reagents for the life science industry. The firm?s products include restriction endonucleases, PCR, qPCR and amplification technologies, DNA modifying enzymes, sample preparation for next generation sequencing, nucleic acid purification, DNA assembly, cloning and mutagenesis kits, genome editing, competent cells, markers and ladders, RNA reagents, gene expression, cellular analysis, epigenetics, protein tools, DNA plasmids, glycobiology, protein expression and purification technologies. The company was founded by Donald Comb in 1974 and is headquartered in Ipswich, MA. | Process Industries |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Palmer & Dodge LLP | Commercial Services |
Magenta Therapeutics, Inc.
Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Thomas Beetham